Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT07772960
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Alcohol Use Disorder (AUD)
  • Obesity (BMI Equal to or >30)

Eligibility Criteria

Sex
ALL
Age
18 Years - 68 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.

Key Dates

First listed
Aug 19, 2026
Start date
Oct 1, 2026
Status verified
Aug 2026
Primary completion
Oct 31, 2031
Completion
Oct 31, 2031

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Placebo Comparator: Placebo
    Placebo saline pen administered weekly for 20 weeks
  • Active Comparator: Semaglutide 1.0 mg
    Semaglutide low dose of 1.0 mg administered weekly over the 20-weeks trial
  • Active Comparator: Semaglutide 2.0 mg
    Semaglutide high dose 2.0 mg administered weekly over the 20-weeks trial

Primary Outcome Measure

Alcohol use days [ Time Frame: 20 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Yale Stress CenterNew HavenConnecticut06519-

Find similar trials in New Haven, CT

By research site
Yale Stress Center· New Haven, CT

Related Studies